Picture loading failed.

Anti-IL6R;ALB therapeutic antibody (Pre-made Vobarilizumab biosimilar,Bispecific Single Domains (VH-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-625-1mg 1mg 3090
GMP-Bios-ab-625-10mg 10mg 21890
GMP-Bios-ab-625-100mg 100mg 148000
GMP-Bios-ab-625-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL6R;ALB therapeutic antibody (Pre-made Vobarilizumab biosimilar,Bispecific Single Domains (VH-VH'))
INN Name Vobarilizumab
TargetIL6R;ALB
FormatBispecific Single Domains (VH-VH')
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCna
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesAblynx
Conditions Approvedna
Conditions ActiveRheumatoid arthritis;Systemic lupus erythematosus
Conditions Discontinuedna
Development TechNanobody Technology